Refining the use of warfarin through genetic testing.
Lee
S C
SC
D000925:Anticoagulants / Q000009:adverse effects* / Q000493:pharmacokinetics; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics* / Q000378:metabolism; D065729:Cytochrome P-450 CYP2C9; D004348:Drug Labeling; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing; D006470:Hemorrhage / Q000139:chemically induced / Q000201:enzymology / Q000235:genetics; D006801:Humans; D006899:Mixed Function Oxygenases / Q000235:genetics* / Q000378:metabolism; D018579:Patient Selection; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D018570:Risk Assessment; D064417:Vitamin K Epoxide Reductases; D014859:Warfarin / Q000009:adverse effects* / Q000493:pharmacokinetics
D000925:Anticoagulants; D014859:Warfarin; D006899:Mixed Function Oxygenases; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D064417:Vitamin K Epoxide Reductases